Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$87.5K Buy
1,218
+21
+2% +$1.98K 0.02% 164
2026
Q1
$141K Buy
+1,197
New +$148K 0.04% 150

Other funds holding ZTS

Bard Associates's ZTS Position: Q2 2026 in Review

Bard Associates increased its Zoetis (ZTS) stake by 1.8% in Q2 2026, buying an estimated $1.98K and bringing the position to 1,218 shares worth $87.5K. The position accounts for 0.02% of the portfolio, ranked #164.

Bard Associates first reported a position in ZTS in Q1 2026 and has held it in 2 quarters since. The position peaked at $141K in Q1 2026. 1,427 funds tracked by Wall St. Rank hold ZTS as of Q2 2026.

  • Bard Associates held 1,218 shares of Zoetis worth $87.5K as of Q2 2026.
  • Bard Associates bought 21 Zoetis shares in Q2 2026, an estimated $1.98K.
  • Zoetis made up 0.02% of Bard Associates's portfolio in Q2 2026, its #164 holding.
  • Bard Associates first reported a position in Zoetis in Q1 2026 and has held it in 2 quarters since.
  • Bard Associates's Zoetis position peaked at $141K in Q1 2026.
  • 1,427 funds tracked by Wall St. Rank held Zoetis as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.